The Wisconsin medical device company NeuWave Medical has raised more than $5.5 million ahead of its sales efforts for a cancer treatment that recently won federal approval, according to regulatory filings.

The U.S. Food and Drug Administration in late October granted a 510(k) marketing clearance for NeuWave’s Certus 140TM 2.45 GHz Ablation System. The device attacks tumors with microwave energy in a way that cuts treatment times, can more accurately target tissue and utilizes a smaller-diameter needle, according to the company.

NeuWave said in November it would begin selling the Certus device in January. While the company closed on $5.5 million in funding, it could raise up to $8 million, according to its filing with the Securities and Exchange Commission.

Wisconsin’s Venture Investors is among the investors in NeuWave.

Copyright 2013 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.